Immutep (NASDAQ:IMMP) has been given a $5.00 target price by stock analysts at Maxim Group in a note issued to investors on Thursday, March 15th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target suggests a potential upside of 179.33% from the company’s current price.
Shares of IMMP stock traded up $0.02 during mid-day trading on Thursday, hitting $1.79. The company’s stock had a trading volume of 18,234 shares, compared to its average volume of 69,154. Immutep has a 52-week low of $1.25 and a 52-week high of $2.85.
ILLEGAL ACTIVITY NOTICE: “Maxim Group Analysts Give Immutep (NASDAQ:IMMP) a $5.00 Price Target” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/immutep-immp-pt-set-at-5-00-by-maxim-group.html.
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.
Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.